New EMA conflicts of interests policy could curtail patient expert advice, says EFPIA
This article was originally published in Scrip
The European Medicines Agency is toughening its conflicts of interests policy to further ensure that its scientific experts do not have links to the pharmaceutical industry that affect their impartiality. However, the industry is concerned that a lack of clarity in the new policy may end up in a shortage of patient experts who are able to "feedback" to either the agency or pharmaceutical companies.
You may also be interested in...
WTO member states including the EU, the US and the UK argue that waiving certain IP rights is unnecessary for enhancing responses to the Covid-19 pandemic.
Insurers argue that better use of real world data and multiple pricing assessments could help lower drug prices in Germany.
To keep investors happy, companies will have to start showing that their high-priced advanced therapies offset costs elsewhere in the health care system.